SynthesisFrontiers in physiology2026
Aluminium neurotoxicity beyond the brain: a mechanistic systematic review of autonomic and peripheral dysfunction.
Synthesis in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aluminium (Al) is a ubiquitous environmental neurotoxicant primarily recognized for its role in central nervous system (CNS) dysfunction. However, emerging evidence suggests that the autonomic (ANS) and peripheral (PNS) nervous systems may be susceptible to Al-induced damage earlier than the CNS, offering potential windows for early detection. This mechanistic systematic review synthesizes current human, animal, and mechanistic evidence to evaluate the multisystemic effects of Al beyond the CNS and to identify potential candidate markers of exposure. Following PRISMA guidelines, a comprehensive search was conducted across five databases (PubMed/MEDLINE, Embase, Scopus, Web of Science, and Cochrane Library). Sixteen primary studies that met strict inclusion criteria were analyzed. Given the heterogeneity of the data, a mechanistic synthesis was employed to map pathways and link them to clinical observations. Synthesis of the evidence reveals a consistent "Barrier-Stress Axis." Mechanistically, Al targets tight junction proteins (e.g., occludin, claudin-5) in the blood-brain and blood-nerve barriers, leading to oxidative stress in the nucleus tractus solitarius and peripheral nerves. Clinically, this manifests as reduced heart rate variability (HRV) and impaired baroreflex sensitivity in both occupational human cohorts and experimental rat models. While peripheral nerve conduction changes are noted, human data remain limited by small sample sizes and confounding environmental factors. Preliminary evidence suggests that ANS and PNS dysregulation may precede overt cognitive decline in Al toxicity. HRV and baroreflex sensitivity are promising candidates for early-stage screening. However, these findings should currently be viewed as hypothesis-generating; longitudinal human studies are required to validate these markers and control for occupational co-exposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.